Claris Life gets healthier after USFDA's successful audit

Claris Lifesciences gained 1.97% to Rs 333.50 at 11:15 IST on BSE after the company announced that it underwent a successful USFDA Pharmacovigilance audit.

The announcement was made during market hours today, 1 June 2017. The stock has snapped two-day losing streak.

Meanwhile, the S&P BSE Sensex was up 20.60 points, or 0.07%, to 31,166.40. The S&P BSE Small-Cap index was up 136.94 points, or 0.91%, to 15,217.15.

On the BSE, 12,568 shares were traded on the counter so far as against the average daily volumes of 81,022 shares in the past one quarter. The stock had hit a high of Rs 338 and a low of Rs 327.90 so far during the day.

The stock hit a record high of Rs 430.10 on 16 December 2016. The stock hit a 52-week low of Rs 188 on 24 June 2016.

The stock had underperformed the market over the past one month till 31 May 2017, falling 7.7% compared with 4.1% gains in the Sensex. The scrip had also underperformed the market in past one quarter, gaining 2.32% as against Sensex's 8.36% gains. The scrip had, however, outperformed the market in past one year, gaining 49.89% as against Sensex's 16.79% gains.

The small-cap company has an equity capital of Rs 54.57 crore. Face value per share is Rs 10.

Claris Lifesciences (CLL) along with its wholly owned subsidiary Claris Injectables (CIL) announced that it underwent a successful United States Food & Drug Administration (USFDA) Pharmacovigilance (PV) audit from 29th May to 31st May 2017, with no observation (i483s).

Claris Lifesciences reported consolidated net profit of Rs 36.96 crore in Q4 March 2017 compared with net loss of Rs 0.62 crore in Q4 March 2016. Net sales fell 75.8% to Rs 4.41 crore in Q4 March 2017 over Q4 March 2016.

Claris Lifesciences is holding company of Claris Injectables, a wholly-owned subsidiary dealing in specialty injectables business. It is also the holding company of Claris Otsuka Private Limited, a joint venture with Japan's Otsuka Pharmaceutical Factory, Inc. and Mitsui & Co. for Infusion business in India and emerging markets.

Powered by Capital Market - Live News